score_bin	sensitive_predictive_implication	resistance_predictive_implication	prognostic_predictive_implication	feature_type	feature	alteration_type	alteration	tumor_f	total_coverage	exac_af	exac_common	clinvar	sensitive_score_bin	sensitive_therapy_name	sensitive_therapy_strategy	sensitive_therapy_type	sensitive_description	sensitive_citation	sensitive_url	resistance_score_bin	resistance_therapy_name	resistance_therapy_strategy	resistance_therapy_type	resistance_description	resistance_citation	resistance_url	prognostic_score_bin	favorable_prognosis	prognostic_description	prognostic_citation	prognostic_url	number_germline_mutations_in_gene	validation_total_coverage	validation_tumor_f	validation_detection_power	feature_display	preclinical_efficacy_observed	patient_id	tumor_sample_barcode	normal_sample_barcode
Putatively Actionable	Preclinical			Copy Number	CCNE1	Amplification				0.0	0.0		Putatively Actionable	Bortezomib	Proteasome inhibition	Targeted therapy	Sensitivity to Bortezomib was observed in ovarian cancer cell lines.	"Etemadmoghadam, Dariush, et al. ""Synthetic lethality between CCNE1 amplification and loss of BRCA1."" Proceedings of the National Academy of Sciences 110.48 (2013): 19489-19494."	https://doi.org/10.1073/pnas.1314302110													0				CCNE1 Amplification	1.0	Osteosarcoma-LA108	LA108_T	
Investigate Actionability	Preclinical			Rearrangement	RUNX1	Fusion	HDAC7--RUNX1			0.0	0.0		Investigate Actionability	Azacitidine + Panobinostat	Hypomethylating agent chemotherapy + HDAC inhibition	Combination therapy	t(8;21)(q22;q22) results in the expression of fusion protein RUNX1-RUNX1T1, which recruits histone deacetylases (HDAC) to silence RUNX1 target genes (such as IL-3). Combined use of HDAC inhibitors and DNMT inhibitors may rescue RUNX1 target genes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf													0				HDAC7--RUNX1 Fusion		Osteosarcoma-LA108		
Biologically Relevant				Copy Number	FLCN	Amplification				0.0	0.0																					0				FLCN Amplification		Osteosarcoma-LA108	LA108_T	
Biologically Relevant				Microsatellite Stability	Supporting variants		PRDM2 p.703_704insP (Insertion), MSH3 p.PPA66del (Deletion)																									0				Supporting variants: PRDM2 p.703_704insP (Insertion), MSH3 p.PPA66del (Deletion)		Osteosarcoma-LA108		
Biologically Relevant				Mutational Signature	COSMIC Signature 1	version 2	0.541																									0				COSMIC Signature (version 2) 1 (54%)		Osteosarcoma-LA108		
Biologically Relevant				Mutational Signature	COSMIC Signature 15	version 2	0.229																									0				COSMIC Signature (version 2) 15 (23%)		Osteosarcoma-LA108		
